Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1293 | Dysphagia Handicap Index (DHI) Wiki | 1.00 |
| drug4226 | Videofluoroscopy Wiki | 1.00 |
| drug1528 | Fibreoptic Endoscopic Evaluation of Swallowing (FEES) Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D006685 | Hoarseness NIH | 1.00 |
| D055154 | Dysphonia NIH | 1.00 |
| D014832 | Voice Disorders NIH | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001618 | Dysphonia HPO | 1.00 |
| HP:0001621 | Weak voice HPO | 1.00 |
| HP:0002015 | Dysphagia HPO | 0.41 |
Navigate: Correlations HPO
There is one clinical trial.
This study examines the presence, severity and natural history of dysphagia and dysphonia in the post-extubation and severely unwell COVID-19 patient.
Description: Based on therapy outcome measures from FEES, VoiS
Measure: Primary endpoint is severity of dysphonia and dysphagia at the time of initial assessment t = day 0 (for ITU patients: Day 0 = 24 hours after extubation or decannulation). Time: t = day 0 (for ITU patients: Day 0 = 24 hours after extubation or decannulation).Description: Clinical assessment including outcome measures, FEES and/or Videofluoroscopy
Measure: The severity of dysphonia and/or dysphagia over an initial 12 month period (at t = 14 days, 1 month, 3 months, 6 months, 9 months, 12 months) Time: t = 14 days, 1 month, 3 months, 6 months, 9 months, 12 monthsDescription: Clinical assessment including outcome measures, FEES and/or Videofluoroscopy
Measure: The severity of dysphonia and/or dysphagia at t = day 5, day 10, day 14, day 21 - For in-patients only. Time: t = day 5, day 10, day 14, day 21 - For in-patients only.Description: Clinical assessment including outcome measures, FEES and/or Videofluoroscopy
Measure: Relationship between severity of dysphonia and/or dysphagia with grade of ARDS Time: t = day 0 and 9 monthsDescription: Clinical assessment including outcome measures, FEES and/or Videofluoroscopy
Measure: Relationship between severity of dysphonia and/or dysphagia with length of intubation Time: t = day 0 and 9 monthsDescription: Clinical assessment including outcome measures, FEES and/or Videofluoroscopy
Measure: Relationship between severity of dysphonia and/or dysphagia with duration of mechanical ventilation Time: t = day 0 and 9 monthsDescription: Questionnaire assessment: This is a 30-item validated quality of life tool that is also a self-reporting tool. It appraises the impact of the patient's abnormal voice from an emotional perspective, related physical symptoms and stratifies the impairment itself in context of day to day activities. VoiSS is currently the most psychometrically robust voice outcome measure. Each item is scored 0 - 4 on the frequency responses: never, occasionally, some of the time, most of the time, always. The total score of 120 measures general voice pathology which is made up of Impairment = maximum score of 60; Emotional = maximum score of 32; Physical = maximum score of 28
Measure: Relationship between severity of dysphonia on quality of life using Voice Symptom Scale (VoiSS) questionnaire over time at day 0, 1 month and 9 months. Time: t = day 0, 1 month and 9 months.Description: Questionnaire assessment: This is a 25-item questionnaire assessing three domains: physical (9 items), functional (9 items), and emotional aspects (7 items) of the Quality of Life (QOL) in patients suffering with dysphagia. For each statement the patient checks if it applies to him/her all the time, some of the time or never. The suggested scores are 0, 2 and 4, respectively. Using this scoring system amounts to a DHI score range of 0 - 100. The higher the score, the worse the dysphagia related QOL. The patient is also asked to provide a rating of their own impression of the severity of the dysphagia experienced on a scale from 1 (normal) to 7 (severe problem).
Measure: Relationship between severity of dysphagia on quality of life using Dysphagia Handicap Index (DHI) questionnaire over time at day 0, 1 month and 9 months Time: t = day 0, 1 month and 9 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports